Accelerating Therapeutic DiscoveryTM

Vision of The Alpha-1 Project

The vision of the future for The Alpha-1 Project (TAP) focuses on the complete cure for Alpha-1 Antitrypsin Deficiency.

To create a world without the effects of COPD and liver disease caused by Alpha-1 Antitrypsin Deficiency.

Mission of The Alpha-1 Project

The mission of The Alpha-1 Project describes the collaborative nature of the pursuit of our vision and how the initiative will build upon the current knowledge base that has been established through projects funded by the Alpha-1 Foundation and/or other organizations.

The Alpha-1 Project will work with patients, academia, pharmaceutical and biotech companies, and public health organizations in the relentless pursuit of cures and therapies for COPD and liver diseases caused by Alpha-1 Antitrypsin Deficiency.

About The Alpha-1 Project

The Alpha-1 Project (TAP) is a wholly owned subsidiary of the Alpha-1 Foundation singularly focused on bridging the gap between clinical trials and commercialization of therapies for the elimination of Chronic Obstructive Pulmonary Disease (COPD) and liver disease caused by Alpha-1 Antitrypsin Deficiency (Alpha-1).

Learn More

Latest News

Posted on November 18, 2019
Arrowhead Pharmaceuticals Inc., has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical...
Posted on August 08, 2019

General Contact

The Alpha-1 Project

3300 Ponce de Leon Boulevard
Coral Gables, FL 33134
Phone: 305-648-9541
Toll-free: 888-920-0002
Fax: 305-441-2110